Savan Devani

Savan Devani is the Founder and CEO of BioTrillion, a health technology company developing a digital biomarker platform called BioEngine4D to digitally detect developing diseases. Previously, Savan spent the majority of his 15 year career in the Life Sciences industry working with hundreds of public and private corporations as a healthcare investment banker with Citigroup and Deutsche Bank. From Analyst through Managing Director, Savan led 40 financing and M&A deals, totaling $35 billion in deal value, and learned many invaluable lessons working with clients across the drug, diagnostic, and device spectrum, such as Amgen, Eli Lilly, Fosun, Masimo, Medtronic, Pacific Biosciences, Xenoport, and many others. Savan began his career as a little bioengineer in a big lab at Life Technologies. Savan graduated with a B.S.E. in Bioengineering from the University of California at Berkeley and a M.S.E. in Bioengineering from the University of Pennsylvania. After many years of academic and professional experience in the healthcare field, a deeply personal experience later in life made Savan truly realize how much in healthcare needed to change – his mother was suddenly diagnosed with stage IVb cancer. This compelled Savan to ask “where were all the signs” and “isn’t there a better way,” which led to BioTrillion.